Ho, ho, holy cow there were a lot of deals last week! In case you missed any on account of snow-shoveling, shopping, or hall-decking, here’s a recap:
—Bristol-Myers Squibb (NYSE: [[ticker:BMY]]) agreed to sell its Billerica, MA-based medical imaging division to private equity firm Avista Capital Partners for some $525 million.
—Burlington, MA’s iRobot (NASDAQ: [[ticker:IRBT]]) inked a deal worth up to $286 million to supply bomb-detection robots to the Army. The deal came in the midst of a certain amount of, let’s say, drama.
—Second Wind, a Somerville, MA-based maker of “sodar” devices for measuring wind conditions, announced a $4 million second-round financing from renewable energy investor Good Energies.
—Brookfield, CT’s Validus DC Systems raised a first round, worth $10 million, from a syndicate led by Oak Hill Venture Partners.
—Library-management-software firm Inmagic of Woburn, MA, announced a $5 million investment from New Jersey-based Edison Venture Fund.
—Framingham, MA-based GlassHouse Technologies stuck its toe in the virtualization IPO waters that VMware recently found so warm by registering for an IPO worth up to $100 million.
—Nuance Communications (NASDAQ: [[ticker:NUAN]]) of Burlington, MA cut size of its planned secondary stock offering almost in half.
—Cambridge, MA-based Elixir Pharmaceuticals set the price range for its 5 million share IPO at between $14 and $16 per share.
—North Andover, MA-based Acquia, which aims to market software and services built around the open-source Web publishing system Drupal, raised $7 million in a first round of financing led by North Bridge Venture Partners.
—Idera Pharmaceuticals (NASDAQ: [[ticker:IDRA]]) forged a drug-development deal potentially worth more than $400 million with Germany’s Merck KGaA.
—Altus Pharmaceuticals (NASDAQ:[[ticker:ALTU]]) took a stock-market nosedive after announcing its deal with Genentech around a human growth hormone deal has lapsed.
